Fischer Medical Ventures Makes Dual Exchange Debut, Stock Climbs Over 2% 

Mumbai, 10 July 2025: Fischer Medical Ventures Limited marked a significant milestone today as its equity shares were officially listed on the National Stock Exchange (NSE), expanding from its existing presence on the Bombay Stock Exchange (BSE). The move signals greater visibility for the company and opens access to a broader pool of investors, coinciding with a positive response in the market.

NSE Listing Confirmed, Trading Begins Under Symbol ‘FISCHER’

Fischer Medical Ventures Limited has announced the listing of its 6,48,51,547 equity shares, each with a face value of ₹10, on the NSE’s Main Board starting 10 July 2025. These shares, fully paid-up and allotted under the designated symbol “FISCHER,” are now available for trading in the EQ series.

• The equity shares are listed under ISIN INE771F01025
• Market lot for trading: 1 share
• All shares are held in compulsory dematerialised form
• Shares will trade in the Normal Market segment (Rolling Settlement)

This dual listing enhances liquidity and provides greater reach among institutional and retail investors.

Fischer Shares Open Higher, Register 2.51% Gain on BSE

Following the NSE debut announcement, Fischer Medical Ventures shares saw a sharp surge in early BSE trading.

• Opening price: ₹810.95
• Day’s high: ₹845.00
• Day’s low: ₹797.00
• Previous close: ₹794.80
• Closing price: ₹814.75 (up ₹19.95 / 2.51%)
• Total traded shares: 21,120
• Total number of trades: 541
• Turnover: ₹1.72 crore

This positive movement reflects growing investor confidence in the company’s growth outlook and enhanced market accessibility.

Shareholder Structure: Lock-in Periods Reflect Promoter Commitment

As per the NSE circular dated 8 July 2025, a structured lock-in schedule has been laid out for a significant portion of the company’s equity. This structure demonstrates long-term commitment by key stakeholders while allowing for a phased release of shares into the market.

• 19.6 lakh shares are currently free from lock-in restrictions
• 54.25 lakh shares are locked-in until 30 September 2025
• 4 crore shares remain restricted until 30 August 2025
• 1.03 crore shares will be released by 15 November 2025
• Remaining shares will be unlocked in tranches through 29 and 30 November 2025

This phased release supports market stability and gradual distribution of equity.

Company Profile: Focused on Medical Innovation and Diagnostic Technology

Fischer Medical Ventures Limited, formerly Fischer Chemic Limited, operates in the Medical Equipment & Supplies sector. The company is strategically positioned in the fast-evolving healthcare and medtech domain.

Fischer Medical has carved a niche in high-end diagnostic and imaging technologies, with a growing footprint in medical innovation hubs like the Andhra Pradesh MedTech Zone.

Strong Opening Interest Suggests Bullish Sentiment

Market activity during the opening session pointed to a robust investor appetite:

• Buy orders: 10,897 shares
• Sell orders: 1,991 shares
• Initial traded volume: 0.01 lakh shares
• Value traded: ₹0.06 crore
• Market capitalisation (early estimates): ₹5,441.04 crore

The demand-supply gap and early price discovery suggest continued investor enthusiasm following the dual listing development.

Looking Ahead: Increased Market Participation and Broader Exposure

With the NSE listing now effective, Fischer Medical Ventures is expected to benefit from wider institutional participation, improved liquidity, and higher brand visibility. Investors now have the opportunity to trade the stock across both BSE and NSE platforms, enhancing accessibility and efficiency.

The company’s ongoing product development in advanced diagnostic systems and its strategic base in India’s MedTech corridors position it for long-term value creation.

As trading activity increases and more shares come out of lock-in, the market will closely watch Fischer Medical Ventures for performance and corporate developments in the medtech space

REF: https://www.bseindia.com/xml-data/corpfiling/AttachLive/b2d520f8-b422-4d76-b526-18cead0202bc.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations